The SUSTAIN-6 trial, which included over 3,000 participants with type 2 diabetes at high cardiovascular risk, showed that Ozempic reduced the risk of major adverse cardiovascular events compared to placebo
First, SELECT was not a primary prevention trial, and the data should not be extrapolated to all individuals with overweight and obesity to prevent major adverse CV events
It provides a compelling option for patients who may need an extra edgethose struggling with fatigue, seeking to optimize their body composition, or needing enhanced metabolic support
Sn xut bi: Ferngrove Pharmaceutical Australia Pty Ltd
Price significantly below market rate: A legitimate single-peptide sermorelin protocol from a licensed compounding pharmacy costs several hundred dollars per cycle
Design of the TRIUMPH Phase 3 Program for Retatrutide